JP2008533151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533151A5 JP2008533151A5 JP2008501948A JP2008501948A JP2008533151A5 JP 2008533151 A5 JP2008533151 A5 JP 2008533151A5 JP 2008501948 A JP2008501948 A JP 2008501948A JP 2008501948 A JP2008501948 A JP 2008501948A JP 2008533151 A5 JP2008533151 A5 JP 2008533151A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- amide
- benzimidazole
- imidazol
- benzimidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- -1 {4- [2- (1H- benzimidazol-2-yl) - ethylcarbamoyl]-1H-benzimidazol-2-yl} - amide Chemical compound 0.000 claims 4
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 3
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 2
- 206010012239 Delusion Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 231100000868 delusion Toxicity 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000007406 plaque accumulation Effects 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- REDRQHKMLWLDKF-UHFFFAOYSA-N 2-(isoquinolin-3-ylamino)-n-(4-methoxyphenyl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 REDRQHKMLWLDKF-UHFFFAOYSA-N 0.000 claims 1
- DPZXAHOQZNGFFO-UHFFFAOYSA-N 2-(isoquinolin-3-ylamino)-n-phenyl-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NC1=CC=CC=C1 DPZXAHOQZNGFFO-UHFFFAOYSA-N 0.000 claims 1
- BXQYWBDHNSYVRY-UHFFFAOYSA-N 2-[(1,5-dimethylindole-2-carbonyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC(C)=CC=C2N(C)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 BXQYWBDHNSYVRY-UHFFFAOYSA-N 0.000 claims 1
- UFJMFVZQYLOJFB-UHFFFAOYSA-N 2-[(1-benzylindole-2-carbonyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(CC=2C=CC=CC=2)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 UFJMFVZQYLOJFB-UHFFFAOYSA-N 0.000 claims 1
- BTFKPFGRLMNQNW-UHFFFAOYSA-N 2-[(2-chlorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 BTFKPFGRLMNQNW-UHFFFAOYSA-N 0.000 claims 1
- XNXBQZHJNSDVQM-UHFFFAOYSA-N 2-[(2-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 XNXBQZHJNSDVQM-UHFFFAOYSA-N 0.000 claims 1
- PUFIGMFPXPZODO-UHFFFAOYSA-N 2-[(3,4-dimethoxybenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 PUFIGMFPXPZODO-UHFFFAOYSA-N 0.000 claims 1
- YYCWDBDINNAQTH-UHFFFAOYSA-N 2-[(3,5-difluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 YYCWDBDINNAQTH-UHFFFAOYSA-N 0.000 claims 1
- YQZGCJOCTVTNGB-UHFFFAOYSA-N 2-[(3-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 YQZGCJOCTVTNGB-UHFFFAOYSA-N 0.000 claims 1
- QBRTUDWKEZRWNB-UHFFFAOYSA-N 2-[(4-chlorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=C(C(=O)NC=3NC=CN=3)C=CC=C2N1 QBRTUDWKEZRWNB-UHFFFAOYSA-N 0.000 claims 1
- UEGPDKFYZHJHSK-UHFFFAOYSA-N 2-[(4-fluoro-3-methoxybenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=C(F)C(OC)=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 UEGPDKFYZHJHSK-UHFFFAOYSA-N 0.000 claims 1
- NRBIGPPBQPOAIW-UHFFFAOYSA-N 2-[(4-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 NRBIGPPBQPOAIW-UHFFFAOYSA-N 0.000 claims 1
- MKUUBNAKDGUWGG-UHFFFAOYSA-N 2-[(4-tert-butylbenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 MKUUBNAKDGUWGG-UHFFFAOYSA-N 0.000 claims 1
- BONUWFJMAMKJBS-UHFFFAOYSA-N 2-[[2-(4-fluorophenyl)acetyl]amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 BONUWFJMAMKJBS-UHFFFAOYSA-N 0.000 claims 1
- FLXAMFSUBWKOGC-UHFFFAOYSA-N 2-amino-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=12NC(N)=NC2=CC=CC=1C(=O)NC1=NC=CN1 FLXAMFSUBWKOGC-UHFFFAOYSA-N 0.000 claims 1
- SIOYHWABOSESEJ-UHFFFAOYSA-N 2-benzamido-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 SIOYHWABOSESEJ-UHFFFAOYSA-N 0.000 claims 1
- RJBYQNGSOBFWIL-UHFFFAOYSA-N 2-isoquinolin-3-yl-n-(5-phenyl-1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2NC(C=3N=CC4=CC=CC=C4C=3)=NC=2C=1C(=O)NC(NC=1)=NC=1C1=CC=CC=C1 RJBYQNGSOBFWIL-UHFFFAOYSA-N 0.000 claims 1
- MIPKQHRPGRGBIU-UHFFFAOYSA-N 6,7-dimethoxyisoquinoline-3-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C=C(OC)C(OC)=CC2=C1 MIPKQHRPGRGBIU-UHFFFAOYSA-N 0.000 claims 1
- 229940124810 Alzheimer's drug Drugs 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000007131 anti Alzheimer effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- AOOXGPCQXPZOMB-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(1h-indole-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC=C2NC(C(NC=3NC4=CC=CC(=C4N=3)C(=O)NC=3NC4=CC=CC=C4N=3)=O)=CC2=C1 AOOXGPCQXPZOMB-UHFFFAOYSA-N 0.000 claims 1
- KMDDVYGNFWMWCX-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=O)C(C=C1N2)=CC=C1N=C2NC1=CC=CC=N1 KMDDVYGNFWMWCX-UHFFFAOYSA-N 0.000 claims 1
- KNAXPDGBZIEBTP-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-naphthalen-2-yl-3h-benzimidazole-5-carboxamide Chemical compound C1=CC=CC2=CC(C=3NC4=CC=C(C=C4N=3)C(NC=3NC4=CC=CC=C4N=3)=O)=CC=C21 KNAXPDGBZIEBTP-UHFFFAOYSA-N 0.000 claims 1
- UKVNFJNGGMOKPQ-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-pyridin-2-yl-3h-benzimidazole-5-carboxamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=O)C(C=C1N=2)=CC=C1NC=2C1=CC=CC=N1 UKVNFJNGGMOKPQ-UHFFFAOYSA-N 0.000 claims 1
- UTXQATYHCDTLPU-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(1h-indole-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 UTXQATYHCDTLPU-UHFFFAOYSA-N 0.000 claims 1
- BCQWSULEBBKAMJ-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NC1=NC=CN1 BCQWSULEBBKAMJ-UHFFFAOYSA-N 0.000 claims 1
- GDDDHZOHBVARSC-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(isoquinolin-3-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2N=C(NC=3N=CC4=CC=CC=C4C=3)NC2=CC=1C(=O)NC1=NC=CN1 GDDDHZOHBVARSC-UHFFFAOYSA-N 0.000 claims 1
- ADHBNWAYMZEQSF-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(naphthalene-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 ADHBNWAYMZEQSF-UHFFFAOYSA-N 0.000 claims 1
- LLEMLFSSJSZFOR-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2N=C(NC=3N=CC=CC=3)NC2=CC=1C(=O)NC1=NC=CN1 LLEMLFSSJSZFOR-UHFFFAOYSA-N 0.000 claims 1
- IROXPLUVFLJDGO-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(1-methylindole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(C)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 IROXPLUVFLJDGO-UHFFFAOYSA-N 0.000 claims 1
- HWFCVPBQVAHWNK-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(1-propylindole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(CCC)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 HWFCVPBQVAHWNK-UHFFFAOYSA-N 0.000 claims 1
- FDISPZPLEREWPS-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-methoxybenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 FDISPZPLEREWPS-UHFFFAOYSA-N 0.000 claims 1
- FKWFBUSCPMWNPI-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-nitrobenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 FKWFBUSCPMWNPI-UHFFFAOYSA-N 0.000 claims 1
- BZAYJTGSTUVJPM-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-phenoxybenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 BZAYJTGSTUVJPM-UHFFFAOYSA-N 0.000 claims 1
- NQFWEZBPLUCTPE-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-phenylbenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 NQFWEZBPLUCTPE-UHFFFAOYSA-N 0.000 claims 1
- NCUWSQJNQBFGQM-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-propan-2-ylbenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 NCUWSQJNQBFGQM-UHFFFAOYSA-N 0.000 claims 1
- RPUAYSHJAPTPRI-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(5-methyl-1h-indole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC(C)=CC=C2NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 RPUAYSHJAPTPRI-UHFFFAOYSA-N 0.000 claims 1
- YPUOEDZEMODXLR-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(6-phenoxypyridine-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC(OC=2C=CC=CC=2)=NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 YPUOEDZEMODXLR-UHFFFAOYSA-N 0.000 claims 1
- HFHWSAODUBTRNO-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[4-(trifluoromethyl)benzoyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)NC1=NC2=C(C(=O)NC=3NC=CN=3)C=CC=C2N1 HFHWSAODUBTRNO-UHFFFAOYSA-N 0.000 claims 1
- UYKBRBDEUIHXGH-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[5-(2-phenylethynyl)pyridine-3-carbonyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1N=CC(C#CC=2C=CC=CC=2)=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 UYKBRBDEUIHXGH-UHFFFAOYSA-N 0.000 claims 1
- BNCARJAWLUNMPH-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[6-(2-phenylethynyl)pyridine-2-carbonyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC(C#CC=2C=CC=CC=2)=NC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 BNCARJAWLUNMPH-UHFFFAOYSA-N 0.000 claims 1
- VCMBSXHBEUBPMZ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 VCMBSXHBEUBPMZ-UHFFFAOYSA-N 0.000 claims 1
- YEGCIUAOIVAIKE-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 YEGCIUAOIVAIKE-UHFFFAOYSA-N 0.000 claims 1
- OIEBPWKAVOFYAU-UHFFFAOYSA-N n-[4-(1h-benzimidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C1=CC=C2C=NC(C(NC=3NC4=C(C(=O)NC=5NC6=CC=CC=C6N=5)C=CC=C4N=3)=O)=CC2=C1 OIEBPWKAVOFYAU-UHFFFAOYSA-N 0.000 claims 1
- YTIHWBQYPRIIBE-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2C=NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 YTIHWBQYPRIIBE-UHFFFAOYSA-N 0.000 claims 1
- AVBAIVJQGVVFMH-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-6-(3-methylbutanoylamino)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=12N=C(NC(=O)C=3N=CC4=CC=CC=C4C=3)NC2=CC(NC(=O)CC(C)C)=CC=1C(=O)NC1=NC=CN1 AVBAIVJQGVVFMH-UHFFFAOYSA-N 0.000 claims 1
- BMZUPQXUWTYOGL-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-6-[(2-phenylacetyl)amino]-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C(C(=O)NC=2NC=CN=2)=C2NC(NC(=O)C=3N=CC4=CC=CC=C4C=3)=NC2=CC=1NC(=O)CC1=CC=CC=C1 BMZUPQXUWTYOGL-UHFFFAOYSA-N 0.000 claims 1
- DHLGALGXGWELNN-UHFFFAOYSA-N n-[6-(1h-benzimidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C1=CC=C2C=NC(C(=O)NC=3NC4=CC=C(C=C4N=3)C(NC=3NC4=CC=CC=C4N=3)=O)=CC2=C1 DHLGALGXGWELNN-UHFFFAOYSA-N 0.000 claims 1
- MDXUDGLOFAJZRO-UHFFFAOYSA-N n-[6-benzamido-4-(1h-imidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C=CC=CC=1C(=O)NC(C=C1NC(NC(=O)C=2N=CC3=CC=CC=C3C=2)=NC1=1)=CC=1C(=O)NC1=NC=CN1 MDXUDGLOFAJZRO-UHFFFAOYSA-N 0.000 claims 1
- JWMDMOYMTPPOQC-UHFFFAOYSA-N n-benzyl-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NCC1=CC=CC=C1 JWMDMOYMTPPOQC-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66134905P | 2005-03-14 | 2005-03-14 | |
| US60/661,349 | 2005-03-14 | ||
| PCT/US2006/009049 WO2006099379A2 (en) | 2005-03-14 | 2006-03-14 | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011256487A Division JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533151A JP2008533151A (ja) | 2008-08-21 |
| JP2008533151A5 true JP2008533151A5 (enExample) | 2011-02-03 |
| JP5066514B2 JP5066514B2 (ja) | 2012-11-07 |
Family
ID=36694148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501948A Expired - Fee Related JP5066514B2 (ja) | 2005-03-14 | 2006-03-14 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
| JP2011256487A Ceased JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011256487A Ceased JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7893267B2 (enExample) |
| EP (2) | EP1863771B1 (enExample) |
| JP (2) | JP5066514B2 (enExample) |
| CN (1) | CN101142194B (enExample) |
| AU (1) | AU2006223070B2 (enExample) |
| BR (1) | BRPI0608581A2 (enExample) |
| CA (1) | CA2600570C (enExample) |
| ES (1) | ES2400287T3 (enExample) |
| IL (2) | IL185541A (enExample) |
| MX (1) | MX2007011234A (enExample) |
| NZ (1) | NZ561029A (enExample) |
| WO (1) | WO2006099379A2 (enExample) |
| ZA (2) | ZA200707896B (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893267B2 (en) * | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| AU2007215247B2 (en) * | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| NZ570625A (en) | 2006-02-10 | 2011-10-28 | Biomarin Iga Ltd | Treatment of duchenne muscular dystrophy |
| JP5306986B2 (ja) | 2006-03-16 | 2013-10-02 | エボテック （ユーエス） インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| PL2463283T3 (pl) * | 2006-04-20 | 2014-10-31 | Pfizer Prod Inc | Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | Benzimidazole compounds |
| WO2008082003A1 (en) | 2006-12-29 | 2008-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| PL2142529T3 (pl) * | 2007-04-27 | 2014-06-30 | Purdue Pharma Lp | Antagoniści trpv1 i ich zastosowania |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| PL2170396T3 (pl) * | 2007-08-03 | 2017-07-31 | Summit (Oxford) Limited | Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| ES2552733T3 (es) | 2007-11-16 | 2015-12-01 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| FR2925904B1 (fr) * | 2008-01-02 | 2010-01-01 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-6-HETEROCYCLIQUE-IMIDAZO°1,2-a! PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| EP2276761B1 (en) | 2008-04-23 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| CA2729128C (en) * | 2008-07-03 | 2016-05-31 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
| CA2732806A1 (en) * | 2008-08-04 | 2010-02-11 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| JP5764064B2 (ja) | 2008-09-26 | 2015-08-12 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| MX2011004505A (es) | 2008-10-29 | 2011-05-31 | Merck Sharp & Dohme | Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| CN101619058A (zh) * | 2009-01-08 | 2010-01-06 | 上海交通大学 | 一种苯并咪唑-4-酰胺型衍生物 |
| WO2010103306A1 (en) * | 2009-03-10 | 2010-09-16 | Astrazeneca Uk Limited | Benzimidazole derivatives and their use as antivaral agents |
| CA2757415C (en) | 2009-04-02 | 2018-02-06 | Merck Patent Gmbh | Autotaxin inhibitors |
| KR20120028869A (ko) * | 2009-04-27 | 2012-03-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | β-세크레타제 억제제로서 치환된 이미다조［1,2-Ａ］피리딘 유도체, 약제학적 조성물, 및 사용 방법 |
| JP2012525389A (ja) * | 2009-04-27 | 2012-10-22 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法 |
| MX2011012628A (es) * | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. |
| EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| KR101757873B1 (ko) | 2009-08-31 | 2017-07-14 | 이하라케미칼 고교가부시키가이샤 | 피리미디닐아세토니트릴 유도체의 제조 방법 및 그 합성 중간체 |
| AU2010289353B2 (en) | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| JP5543980B2 (ja) | 2009-12-18 | 2014-07-09 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
| WO2011086098A1 (en) | 2010-01-15 | 2011-07-21 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| PH12012501480A1 (en) | 2010-01-25 | 2012-10-22 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8450354B2 (en) | 2010-03-23 | 2013-05-28 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors |
| WO2012018668A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| JP2013542973A (ja) | 2010-11-22 | 2013-11-28 | ノスシラ、ソシエダッド、アノニマ | 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体 |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| CN103717594B (zh) | 2011-06-22 | 2016-12-14 | 普渡制药公司 | 包含二羟基取代基的trpv1拮抗剂及其用途 |
| MX2014000626A (es) * | 2011-07-15 | 2014-04-30 | Janssen Pharmaceuticals Inc | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa. |
| US9216968B2 (en) * | 2011-08-18 | 2015-12-22 | Nippon Shinyaku Co., Ltd. | Heterocyclic derivative and pharmaceutical drug |
| WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| EP2802328B1 (en) * | 2012-01-09 | 2018-03-07 | X-Chem, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| WO2013104577A1 (en) | 2012-01-11 | 2013-07-18 | Acesion Pharma Aps | Benzimidazolyl-acetamide derivatives useful as potassium channel modulators |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| SG11201407051XA (en) | 2012-05-16 | 2014-11-27 | Janssen Pharmaceuticals Inc | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CN103772376B (zh) * | 2012-10-24 | 2017-01-11 | 中国医学科学院医药生物技术研究所 | 取代的苯并-1,3-杂唑类化合物、其制备方法及用途 |
| CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
| EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
| WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
| WO2015004533A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
| CA2931097A1 (en) | 2013-11-19 | 2015-05-28 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| ES2732902T3 (es) | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
| EA031655B1 (ru) | 2014-02-11 | 2019-02-28 | Байер Фарма Акциенгезельшафт | Бензимидазол-2-амины в качестве ингибиторов midhi |
| US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| WO2016062677A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| CA2965213A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824954B2 (ja) | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
| JP6835828B2 (ja) * | 2015-09-18 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用 |
| WO2017049069A1 (en) * | 2015-09-18 | 2017-03-23 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| KR20180094989A (ko) * | 2015-12-15 | 2018-08-24 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| CN106986809B (zh) * | 2016-12-02 | 2020-03-24 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种5-溴-6-氯-3-吲哚辛酯的合成方法 |
| ES2940408T3 (es) | 2017-08-21 | 2023-05-08 | Merck Patent Gmbh | Derivados de benzoimidazol como antagonistas de los receptores de adenosina |
| CN111741954B (zh) * | 2018-02-21 | 2024-04-02 | 勃林格殷格翰国际有限公司 | 用作egfr抑制剂的新型苯并咪唑化合物及衍生物 |
| CN109400528B (zh) * | 2018-12-18 | 2022-03-15 | 深圳科兴药业有限公司 | 一种可博美的合成方法 |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| CN116615425A (zh) * | 2020-09-17 | 2023-08-18 | 诺华股份有限公司 | 作为Sppl2a抑制剂的化合物和组合物 |
| US12227475B2 (en) * | 2021-04-27 | 2025-02-18 | X-Biotix Therapeutics, Inc. | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions |
| IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | Urea derivatives which can be used to treat cancer |
| CN113387959B (zh) * | 2021-06-24 | 2023-05-05 | 烟台理工学院 | 一种噻吩并[3,2-c]吡啶-6-羧酸甲酯的合成方法 |
| WO2024211834A1 (en) * | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Biaryl derivatives and related uses |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401173A (en) | 1966-04-05 | 1968-09-10 | Smith Kline French Lab | Heterocyclic acylaminobenzimidazoles |
| GB1122957A (en) | 1965-06-07 | 1968-08-07 | Smith Kline French Lab | Substituted benzimidazoles and anthelmintic compositions containing them |
| US3336191A (en) | 1966-03-11 | 1967-08-15 | Smith Kline French Lab | Anthelmintic 2-amidobenzimidazoles |
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| US6329163B1 (en) | 1995-06-07 | 2001-12-11 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase inhibition |
| AU6383396A (en) | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| GB9600142D0 (en) * | 1996-01-05 | 1996-03-06 | Wellcome Found | Chemical compounds |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| EP0944616B1 (en) * | 1996-11-15 | 2003-06-04 | Darwin Discovery Limited | Bicyclic aryl carboxamides and their therapeutic use |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| ID24289A (id) * | 1997-11-10 | 2000-07-13 | Bristol Myers Squibb Co | Benzotiazol inhibitor-inhibitor protein terosin kinase |
| US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US20040234976A1 (en) * | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| HK1042730B (zh) * | 1998-09-24 | 2005-11-18 | 法玛西雅厄普约翰美国公司 | 阿尔茨海默氏疾病分泌酶 |
| US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| ATE259789T1 (de) * | 1998-11-27 | 2004-03-15 | Abbott Gmbh & Co Kg | Substituierte benzimidazole und ihre verwendung als parp inhibitoren |
| GB2364059B (en) | 1999-02-10 | 2004-01-14 | Elan Pharm Inc | Beta-Secretase enzyme compositions and methods |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| HRP20010944B1 (hr) * | 1999-06-23 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh | Supstituirani benzimidazoli |
| EP1418175A1 (en) | 1999-06-28 | 2004-05-12 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| DE60045005D1 (de) | 1999-06-28 | 2010-11-04 | Oklahoma Med Res Found | Inhibitoren des memapsin 2 und ihre verwendung |
| AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| EP1222187B1 (en) | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
| US20030143708A1 (en) * | 1999-12-29 | 2003-07-31 | Blatt La Wrence | Method and reagent for the treatment of alzheimer's disease |
| JP2003528071A (ja) | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| AU2001258771A1 (en) * | 2000-05-19 | 2001-11-26 | Takeda Chemical Industries Ltd. | -secretase inhibitors |
| US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| TW200628612A (en) * | 2000-07-19 | 2006-08-16 | Pharmacia & Up John Company | Substrates and assays for β-secretase activity |
| MXPA03001306A (es) | 2000-08-11 | 2003-10-15 | Boehringer Ingelheim Pharma | Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina. |
| WO2002025276A1 (en) | 2000-09-22 | 2002-03-28 | Wyeth | Crystal structure of bace and uses thereof |
| US20020157122A1 (en) * | 2000-10-27 | 2002-10-24 | Wong Philip C. | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
| ATE330950T1 (de) | 2000-12-13 | 2006-07-15 | Wyeth Corp | Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion |
| GB0101313D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| RU2003126913A (ru) * | 2001-02-02 | 2005-03-10 | Шеринг Корпорейшн (US) | 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс |
| EP1233021A3 (en) * | 2001-02-20 | 2002-11-20 | Pfizer Products Inc. | An inhibitor of Beta amyloid cleavage enzyme |
| EP1434988A4 (en) * | 2001-02-23 | 2005-12-14 | Elan Pharm Inc | TRANSGENIC ANIMALS KNOCKOUT WITH GENE BACE-1 INACTIVE |
| WO2002069965A1 (en) | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| US6660741B2 (en) * | 2001-03-19 | 2003-12-09 | Sloan-Kettering Institute For Cancer Research | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| JP2004534017A (ja) * | 2001-04-27 | 2004-11-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｂａｃｅのインヒビター |
| FR2824825B1 (fr) * | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6562783B2 (en) * | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| EP1401439B1 (en) * | 2001-06-25 | 2006-04-19 | Elan Pharmaceuticals, Inc. | Use of bicyclo compounds for treating alzheimer's disease |
| US20030093356A1 (en) * | 2001-07-06 | 2003-05-15 | Assetsight, Inc. | Method for issuing a derivative contract |
| MXPA04000328A (es) | 2001-07-10 | 2004-07-23 | Pharmacia & Upjohn Comapny | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. |
| US20030109559A1 (en) | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
| MXPA04001980A (es) * | 2001-08-28 | 2005-02-17 | Pharmacia & Up John Company | Metodos de tratamiento de la enfermedad de alzheimer usando derivados de quinaldoil.amina de hidrocarburos substituidos con oxo e hidroxi. |
| GB0123379D0 (en) | 2001-09-28 | 2001-11-21 | Lorantis Ltd | Modulators |
| CA2458533C (en) | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| BR0206161A (pt) * | 2001-10-19 | 2005-02-01 | Ortho Mcneil Pharm Inc | 2-fenil benzimidazóis e imidazo-[4,5]-piridinas como inibidores de cds1/chk2 e adjuvantes para quimioterapia ou terapia por radiação no tratamento de câncer |
| AU2002343604C1 (en) | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| IL161881A0 (en) | 2001-11-08 | 2005-11-20 | Upjohn Co | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| EP1448199A1 (en) | 2001-11-09 | 2004-08-25 | Boehringer Ingelheim Pharmaceuticals Inc. | Benzimidazoles useful as protein kinase inhibitors |
| US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| EP1572904B1 (en) * | 2002-02-21 | 2009-04-15 | Pharmacia & Upjohn Company LLC | Modified bace |
| DE60325519D1 (de) * | 2002-03-01 | 2009-02-12 | Hoffmann La Roche | Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit |
| WO2003075921A2 (en) * | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| US20040014194A1 (en) * | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7517875B2 (en) | 2002-04-16 | 2009-04-14 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| EP1572129A4 (en) * | 2002-06-07 | 2007-03-28 | Univ North Carolina | AMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSE |
| KR101052433B1 (ko) | 2002-06-13 | 2011-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 자이라제 및/또는 토포이소머라제 ⅳ 억제제로서의 2-우레이도-6-헤테로아릴-3ｈ-벤조이미다졸-4-카복실산 유도체 및 이를 포함하는 세균 감염 치료용 약제학적 조성물 |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| KR20050037585A (ko) * | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
| CN1732161A (zh) * | 2002-09-06 | 2006-02-08 | 艾伦药物公司 | 1,3－二氨基－2－羟基丙烷前体药物衍生物 |
| UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| AU2003275225A1 (en) * | 2002-09-20 | 2004-04-08 | Genelabs Technologies, Inc. | Novel aromatic compounds possessing antifungal or antibacterial activity |
| MXPA05005649A (es) * | 2002-11-27 | 2005-08-16 | Elan Pharm Inc | Ureas y carbamatos sustituidos. |
| WO2004084830A2 (en) | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
| US20050176792A1 (en) * | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
-
2006
- 2006-03-14 US US11/885,096 patent/US7893267B2/en not_active Expired - Fee Related
- 2006-03-14 EP EP06738139A patent/EP1863771B1/en active Active
- 2006-03-14 BR BRPI0608581-4A patent/BRPI0608581A2/pt not_active IP Right Cessation
- 2006-03-14 ZA ZA200707896A patent/ZA200707896B/xx unknown
- 2006-03-14 JP JP2008501948A patent/JP5066514B2/ja not_active Expired - Fee Related
- 2006-03-14 US US11/374,723 patent/US20060223849A1/en not_active Abandoned
- 2006-03-14 ES ES06738139T patent/ES2400287T3/es active Active
- 2006-03-14 EP EP12150487A patent/EP2457901A1/en not_active Withdrawn
- 2006-03-14 AU AU2006223070A patent/AU2006223070B2/en not_active Ceased
- 2006-03-14 WO PCT/US2006/009049 patent/WO2006099379A2/en not_active Ceased
- 2006-03-14 CA CA2600570A patent/CA2600570C/en not_active Expired - Fee Related
- 2006-03-14 MX MX2007011234A patent/MX2007011234A/es active IP Right Grant
- 2006-03-14 NZ NZ561029A patent/NZ561029A/en not_active IP Right Cessation
- 2006-03-14 CN CN2006800084176A patent/CN101142194B/zh not_active Expired - Fee Related
-
2007
- 2007-08-27 IL IL185541A patent/IL185541A/en not_active IP Right Cessation
-
2009
- 2009-05-13 ZA ZA2009/03300A patent/ZA200903300B/en unknown
-
2010
- 2010-11-19 US US12/950,718 patent/US8598353B2/en not_active Expired - Fee Related
-
2011
- 2011-11-24 JP JP2011256487A patent/JP2012046541A/ja not_active Ceased
-
2012
- 2012-10-25 IL IL222698A patent/IL222698A0/en unknown
-
2013
- 2013-10-28 US US14/064,737 patent/US8946259B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533151A5 (enExample) | ||
| CN105492439B (zh) | 作为溴结构域抑制剂的取代的双环化合物 | |
| CA2600570A1 (en) | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors | |
| JP6436205B2 (ja) | キノリン誘導体 | |
| JP6708130B2 (ja) | キノリン誘導体 | |
| RU2375046C2 (ru) | Твердый состав с улучшенными растворимостью и стабильностью и способ его получения | |
| JP2008524246A5 (enExample) | ||
| JP2009521399A5 (enExample) | ||
| ZA200302918B (en) | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders. | |
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| JP2007513915A5 (enExample) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2011500638A5 (enExample) | ||
| AU2007329480A1 (en) | Indazole compounds | |
| JP2013523792A (ja) | Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ | |
| HRP20140593T1 (hr) | Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori | |
| HUP0303460A2 (hu) | IgE-Módosító és sejtburjánzásgátló hatású benzimidazolok és ezeket tartalmazó gyógyszerkészítmények | |
| KR20140117684A (ko) | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 | |
| JP2020531454A5 (enExample) | ||
| TW201900637A (zh) | N-取代吲哚衍生物 | |
| CN104023715A (zh) | 激酶抑制剂的副作用降低剂 | |
| RU2005136383A (ru) | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов | |
| CN111727044A (zh) | 用于治疗癌症或炎性疾病的杂二环羧酸 | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| PT1487424E (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii |